Project Grant R01HL174945
Award Date
7/15/25
Completion Date
4/28/29
Dollars Obligated
$696K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $720,676 to the University of Pittsburgh to develop a novel nitro-fatty acid-based microbubble (NFAB) therapeutic strategy delivered via ultrasound-targeted microbubble cavitation (UTMC). The goal is to improve ventricular recovery and treat microvascular obstruction and myocardial fibrosis following myocardial infarction. The research aims...
This Project Grant award from the National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $1,082,412 to the University of Pittsburgh to optimize and prepare for the manufacturing and regulatory submission of an immunoregulatory tissue-engineered vascular graft (TEVG) device. The key objectives are to: Evaluate the TEVG constructs in vitro using clinically-relevant measures, 2) Validate the performance of scaled-up, human-sized...
This Project Grant awarded by the National Heart, Lung, and Blood Institute (NHLBI), under CFDA Program 93.837 Cardiovascular Diseases Research, is funding research to develop an ultrasound-based approach for delivering microRNA-92a inhibitor (antimir-92a) to the heart to prevent adverse cardiac remodeling following acute myocardial infarction. The $791,485 award will support experiments in rat and porcine models to define the optimal antimir-92a dose and test the efficacy and safety of...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $758,862 to Yale University to develop a multi-modality imaging approach for guiding the delivery of therapeutic hydrogels to the heart for prevention of remodeling after myocardial infarction (MI). The project aims to employ hybrid SPECT/CT imaging to non-invasively track markers of inflammation and fibroblast activation, and...
This $647,359 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) supports the engineering of biomaterials with controlled biomolecule delivery for cardiovascular applications. The key products and services to be delivered include: Efficient and sustainable delivery of microRNA-145 from a novel biomaterial (PVA-CDI immobilized aminated fucoidan, or PCAF) to smooth muscle cells to induce a contractile...
This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) is funding the development and validation of a new Super-Resolution Intravascular Ultrasound (SR-IVUS) technology to enable high-resolution 3D imaging of the coronary vasa vasorum and thin fibrous cap of vulnerable atherosclerotic plaques. The $726,205 award, granted on April 22, 2025, supports the University of Pittsburgh's efforts to create a dual-mode SR-IVUS catheter...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $767,077 to the University of North Carolina at Chapel Hill to validate and extend a platform technology for the delivery of protein-based drugs, with a focus on thrombolytic enzymes. The research aims to develop a biocompatible drug delivery system that can leverage the circulatory system as a natural drug depot, release the...
This Project Grant award from the National Heart Lung and Blood Institute (CFDA 93.837 - Cardiovascular Diseases Research) aims to develop and test novel hydrogel patches that can prevent air leaks after lung surgery. The $229,971 award, effective February 1, 2025 through January 31, 2027, will support the University of North Carolina at Chapel Hill in optimizing the degradation rate and elastic properties of the hydrogel patches, evaluating their ability to prevent pneumothorax in rat lung...
This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $298,368 to Link Medical LLC to develop a novel device for treating mitral valve regurgitation. The funded project aims to optimize the device design and procedure through bench testing, followed by in vivo feasibility studies. The goal is to create a simpler, more robust, and more effective solution than existing technologies for...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is funding the development of a novel, injectable biomaterial hydrogel to enable sustained delivery of the therapeutic protein neuregulin-1 (NRG1) to the myocardium for the treatment of myocardial infarction (MI). The $769,789 award to The Leland Stanford Junior University will support a 4-year research project to design and evaluate the...